August 29, 2026
RESEARCH USE ONLY. Retatrutide is an investigational compound. It is not approved by the FDA for human or veterinary use. Products discussed on this site are supplied strictly for laboratory and research purposes. Nothing on this page is medical advice, and nothing here is a dosing recommendation for any person or animal.
This question has a clean answer, which is unusual in this category. We checked FDA’s own databases directly rather than repeating what other pages say, and we are showing the queries so the answer is checkable.
No. As of 19 August 2026, retatrutide is not approved by the FDA for any indication. It is an investigational molecule in Phase 3 trials. Its sponsor, Eli Lilly, states publicly that it plans to submit for US approval in the first quarter of 2027.
Sourced fact: A query to FDA’s Drugs@FDA database via the openFDA API for retatrutide returns zero records (HTTP 404, no matches). The identical query for tirzepatide on the same endpoint returns two records — NDA 217806 (Zepbound) and NDA 215866 (Mounjaro) — confirming the database was live and correctly indexed when queried. [1]
Sourced fact: FDA states in its own words that retatrutide and cagrilintide “are not components of FDA-approved drugs and have not been found safe and effective for any condition.” [2] That page was current as of 15 June 2026.
Sourced fact: In a press release dated 23 July 2026, Lilly wrote: “Lilly is completing the comprehensive Chemistry, Manufacturing, and Controls (CMC) data package required for a Biologics License Application (BLA) and plans to subsequently submit retatrutide in Q1 2027 for U.S. approval.” [3]
Sourced fact: Lilly repeated the timeline in its Q2 2026 earnings release of 5 August 2026: “The clinical data package is now complete to support global registrations for obesity, obstructive sleep apnea, and knee osteoarthritis pain, with plans to submit a Biologics License Application to the U.S. FDA in the first quarter of 2027.” [4]
Inference: A stated intention to submit in Q1 2027 means, by definition, that no application was pending as of August 2026. Submission is also not approval — FDA review follows submission, and the outcome of a review that has not begun cannot be known.
This is the part that trips people up, and most pages covering this topic miss it entirely.
Sourced fact: A search of NLM’s DailyMed for retatrutide returns ten Structured Product Labels. All ten come from a single labeler, “GUANGZHOU YIXIN CROSS-BORDER E-COMMERCE CO., LTD.”, all published 17 November 2025, under names including “SALKALLI (RETATRUTIDE PEN 30MG)”. [5]
Sourced fact: Inspecting one of those labels shows its Marketing Category is “Export only”. [6]
Inference: “Export only” is a drug registration-and-listing category. Registering and listing a product is an administrative filing, not an FDA review of safety or efficacy, and it is not an approval. A product can appear in DailyMed and hold no FDA approval whatsoever. Anyone citing “retatrutide has a DailyMed label” as evidence of approval has misread what that database contains. The indication text on those export-only labels has not been evaluated by FDA.
Sourced fact: In a letter to the Federation of State Medical Boards dated 31 March 2025, FDA’s Division of Compounding II wrote: “Retatrutide is not the subject of an applicable USP or NF monograph, is not a component of an FDA-approved drug product, and does not appear on the 503A Bulks List,” and separately that it “does not appear on the 503B Bulks List, nor does it appear on FDA’s drug shortage list.” [7]
Sourced fact: We independently confirmed the absence. Retatrutide does not appear on FDA’s 503A bulk drug substances page (current as of 14 May 2026) [8], the 503B page [9], or the FDA Drug Shortages database [10].
Sourced fact: Lilly lists ten Phase 3 retatrutide trials. [11] Registry status as of August 2026:
| Trial | NCT | Population | Status |
|---|---|---|---|
| TRIUMPH-1 | NCT05929066 | Obesity/overweight | Completed |
| TRIUMPH-2 | NCT05929079 | T2D + obesity | Active, not recruiting |
| TRIUMPH-3 | NCT05882045 | Obesity + CVD | Completed |
| TRIUMPH-4 | NCT05931367 | Obesity + knee OA | Completed |
| TRIUMPH-5 | NCT06662383 | Obesity, vs tirzepatide | Active, primary completion est. Nov 2026 |
| TRIUMPH-Outcomes | NCT06383390 | Obesity + ASCVD/CKD | Active, primary completion est. Feb 2029 |
Sourced fact: Only one Phase 3 retatrutide trial has been published in a peer-reviewed journal — TRANSCEND-T2D-1, in The Lancet, 1 June 2026. [12] Results from TRIUMPH-1 through TRIUMPH-4 exist only as sponsor press releases and conference presentations.
Inference: That distinction matters when weighing evidence. A press release is written by the sponsor and is not peer reviewed. Lilly’s own 21 May 2026 release says “Additional detailed results will be presented at future medical meetings and published in peer-reviewed journals” — which is an acknowledgment that the peer-reviewed record does not yet exist for those trials.
Sourced fact: Retatrutide is not named anywhere in the WADA 2026 Prohibited List. Neither are tirzepatide, semaglutide, “GLP-1,” or “incretin.” [13]
Sourced fact: Section S0 of that list reads: “Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g. drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited at all times.”
Inference: Applying that definition to the approval status established above, retatrutide meets the S0 description on its face as a drug under clinical development. We verified absence of approval with FDA and EMA; we did not survey every national regulator worldwide, so that premise is verified for those two authorities.
Sourced fact: The only EMA record for retatrutide we located is a paediatric investigation plan decision, P/0336/2024, dated 13 September 2024. [14]
Inference: A PIP agreement is a procedural prerequisite to filing, not a marketing authorisation and not an application under evaluation.
This is not medical advice and not a protocol. It reports the contents of FDA databases, FDA correspondence, EMA records, clinical trial registries, and sponsor filings as they stood on 19 August 2026. Regulatory status changes — a stated Q1 2027 submission target means this page has a foreseeable expiry date, and we will update it rather than let it drift.
Questions about whether any compound is appropriate for any person belong with a licensed physician.
PureLab Performance supplies retatrutide and other compounds for laboratory research use. Every compound page publishes its own specification block — lot, chromatographic purity, label claim, identity method and testing laboratory — or states plainly that the certificate is pending. Related reading: what the retatrutide research actually shows and our GLP-1 research reference.
RESEARCH USE ONLY — FULL DISCLAIMER. The products discussed on this page are supplied strictly for laboratory and scientific research purposes. They are not for human or veterinary use, and not for consumption. These statements have not been evaluated by the Food and Drug Administration. Nothing on this page is intended to diagnose, treat, cure, or prevent any disease in humans or animals. Nothing here constitutes medical or veterinary advice or a dosing, preparation, or administration recommendation for any person or animal.
Regulatory status verified 19 August 2026. Trial registry data read via a ClinicalTrials.gov mirror and cross-checked against sponsor documents.
